Following vaginal metronidazole for BV, incidence of recurrence lower with Lactin-V versus placebo
WEDNESDAY, May 13, 2020 (HealthDay News) — For women with bacterial vaginosis, Lactobacillus crispatus CTV-05 (Lactin-V) after vaginal metronidazole results in a lower incidence of recurrence at 12 weeks, according to a study published in the May 14 issue of the New England Journal of Medicine.
Craig R. Cohen, M.D., from the University of California in San Francisco, and colleagues conducted a randomized phase 2b trial to examine the ability of Lactin-V to prevent bacterial vaginosis recurrence. Women aged 18 to 45 years with a diagnosis of bacterial vaginosis who had completed a course of vaginal metronidazole gel were randomly assigned in a 2:1 ratio to receive vaginally administered Lactin-V or placebo for 11 weeks (152 and 76 participants, respectively).
Overall, 88 and 84 percent of the women in the Lactin-V and placebo groups could be assessed for the primary outcome. The researchers found that recurrence of bacterial vaginosis by week 12 occurred in 30 and 45 percent of participants in the Lactin-V and placebo groups, respectively, in the intention-to-treat analysis (risk ratio after multiple imputation for missing responses, 0.66). For recurrence by week 24, the risk ratio was 0.73. L. crispatus CTV-05 was detected in 79 percent of participants in the Lactin-V group at the 12-week visit.
“The use of Lactin-V after treatment with vaginal metronidazole for bacterial vaginosis resulted in a significantly lower incidence of recurrence of bacterial vaginosis at 12 weeks than placebo, and the benefit appeared to persist through week 24,” the authors write.
Copyright © 2020 HealthDay. All rights reserved.
